Analyst Ratings for Mirati Therapeutics (MRTX)
MRTX Rating Summary
MRTX Price Target Summary
- Highest: $75.00 (Barclays)
- Lowest: $37.00 (Morgan Stanley)
- Average: $58.36
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$58.36 (-0.6%)
* Over Last 12-Mos
Rating Score: 3.1 / 10
Percentile Rank: 27%
Avg. $ Target:
$58.36 (-0.6%)
* Over Last 12-Mos
Rating Score: 3.1 / 10
Percentile Rank: 27%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/20/2023 | Citi | Yigal Nochomovitz | Downgrade | Neutral (Buy) |
59.00 (48.00) |
57.80 (58.70) |
1.56% | Details |
| 11/7/2023 | Leerink Partners | Andrew Berens | Downgrade | Market Perform (Outperform) |
58.00 (78.00) |
56.27 (58.70) |
4.32% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
